Merck & Co. Stock Surges on mRNA Melanoma Breakthrough and New Cholesterol Therapy
Merck & Co. stock is gaining momentum following positive long-term Phase 3 results from its individualized mRNA-based melanoma program. The trial, presented at the American Society of Clinical Oncology meeting in September 2026, showed that patients who received Keytruda plus a personalized mRNA vaccine had a 49% lower likelihood of recurrence or death and a 59% drop in distant metastasis or death compared to those receiving Keytruda alone.
The combination therapy demonstrated the potential for durable revenue streams in melanoma if regulators translate these outcomes into broader approvals. This could strengthen Merck & Co.'s oncology moat, extending the life cycle of established immuno-oncology drugs.
Additionally, the company has added a new cardiometabolic pillar with the approval of LIPFENDRA, an oral PCSK9 inhibitor for cholesterol management. This represents a fresh opportunity to compete on convenience and adherence in a segment previously dominated by injectable biologics.